Speaking Engagements

Paul Frohna speaking engagements have included the following:

*2nd International Conference on Translational Medicine, Omics Group.  Session Chair and Speaker: The challenge of genetic diversity in clinical trials: Is precision medicine up to the challenge? Chicago, Illinois, August 2013 http://www.omicsgroup.com/conferences/translational-medicine-2013/scientific-programme.php?day=3&sid=143&date=2013-08-07

* 2nd Annual International Symposium of Hematology: Reconstruct the Fountain of Life, Nourish the Tree of Life. Advisory Board Member and Section Chair and Speaker: Advances in Topical Hemostats for Surgical Bleeding: Phase 2 Experience with Fibrocaps, a Novel, Dry-Powder Fibrin Sealant, http://www.bitlifesciences.com/aish2013/programcommittee.asp

* 1st Annual International Symposium of Hematology: New Opportunities and Challenges in the 21st Century. Advisory Board Member and Section Chair and Speaker: Bleeding, Hemostasis and Thrombosis Disorder Management, Beijing, China, June 2012 http://www.bitlifesciences.com/aish2012

* “Using PK-PD Data from Early Clinical Trials to Prepare for a TQT Study”, Cardiac Safety Workshop, La Jolla, CA, December 2011

* “Development Challenges for a Novel Tissue Sealant Device-Biologic Combination”, FDA- sponsored Two-day Tissue Adhesives / Soft Tissue Workshop / Symposium, Rockville, MD, September 2011

* “PK-PD Modeling with the QTc: Previous Experience and Future Trends”, and Panelist, Cardiac Drug Safety in Japan: Impact of ICH E14, Osaka, Japan, November 2010

* “Laying the Groundwork for a Successful Early Development Program”, and Panelist, Accelerating Early Clinical Development, sponsored by West Coast Clinical Trials, San Mateo, CA, May 2010 http://wcct.com/wp-content/uploads/2010/04/WCCT-Symposia-May-18-San-Francisco.pdf

* Workshop Panelist, Cardiac Safety for Diabetes and Oncology Compounds in Drug Development Meeting, San Diego, CA, February 2010

* “PK Modeling and the QTc: Current Regulatory Thoughts and Directions” and Panelist, Current Issues in Drug Development from a Cardiac Safety Perspective, San Francisco, CA, September 2008

* Meeting Chairperson, Establishing Proof of Concept in Phase 1 Trials, sponsored by Institute for International Research, Boston, MA, October 2007

* “ECG Collection during Early Clinical Development: Practical Considerations of E14” during Avoiding QT Overkill Session, DIA Annual Meeting, June 2006 http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/ucm118776.pdf